Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA129227 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:This SuperSeries is composed of the following subset Series: GSE22366: Primary human erythroid progenitor cells HDAC1 and HDAC2 shRNA knockdown samples GSE22367: Primary human erythroid progenitor cells SAHA treatment samples GSE22368: Primary human erythroid progenitor cells NK57 treatment samples Refer to individual Series
2010-07-29 | E-GEOD-22369 | biostudies-arrayexpress
Project description:Primary human erythroid progenitor cells NK57 treatment samples
| PRJNA129229 | ENA
Project description:Primary human erythroid progenitor cells HDAC1 and HDAC2 shRNA knockdown samples
| PRJNA129225 | ENA
Project description:Gene expression profiling was performed on primary human erythroid progenitor cells left untreated or treated with 0.5uM SAHA. The worldwide burden of sickle cell disease is enormous, with over 200,000 infants born with the disease each year in Africa alone. Induction of fetal hemoglobin is a validated strategy to improve symptoms and complications of this disease. The development of targeted therapies has been limited by the absence of discrete druggable targets. We developed a novel bead-based strategy for the identification of inducers of fetal hemoglobin transcripts in primary human erythroid cells. A small-molecule screen of bioactive compounds identified remarkable class-associated activity among histone deacetylase (HDAC) inhibitors. Using a chemical genetic strategy combining focused libraries of biased chemical probes and reverse genetics by RNA interference, we have identified HDAC1 and HDAC2 as molecular targets mediating fetal hemoglobin induction. Our findings suggest the potential of isoform-selective inhibitors of HDAC1 and HDAC2 for the treatment of sickle cell disease. Gene expression profiling was performed on primary human erythroid progenitor cells left untreated (n=3) or treated with 0.5uM SAHA (n=3).
2010-07-29 | E-GEOD-22367 | biostudies-arrayexpress
Project description:This is a dynamic pathway model examining the roles of of the two transcriptional negative feedback regulators of the suppressor of cytokine signaling (SOCS) family, CIS and SOCS3, in JAK/STAT5 signaling, within the context of primary erythroid progenitor cells.
2019-11-14 | BIOMD0000000861 | BioModels
Project description:ChIP-seq analysis of PRC2 core subunits in primary human erythroid progenitor cells
| PRJNA254354 | ENA
Project description:Gene expression profiling was performed on primary human erythroid progenitor cells left untreated or treated with 0.5uM SAHA. The worldwide burden of sickle cell disease is enormous, with over 200,000 infants born with the disease each year in Africa alone. Induction of fetal hemoglobin is a validated strategy to improve symptoms and complications of this disease. The development of targeted therapies has been limited by the absence of discrete druggable targets. We developed a novel bead-based strategy for the identification of inducers of fetal hemoglobin transcripts in primary human erythroid cells. A small-molecule screen of bioactive compounds identified remarkable class-associated activity among histone deacetylase (HDAC) inhibitors. Using a chemical genetic strategy combining focused libraries of biased chemical probes and reverse genetics by RNA interference, we have identified HDAC1 and HDAC2 as molecular targets mediating fetal hemoglobin induction. Our findings suggest the potential of isoform-selective inhibitors of HDAC1 and HDAC2 for the treatment of sickle cell disease.
2010-06-28 | GSE22367 | GEO
Project description:Reactivation of gamma-globin is considered a promising approach for the treatment of beta-thalassaemia and sickle cell disease. Therapeutic induction of gamma-globin expression is fraught with lack of suitable therapeutic targets. In order to identify new potential targets we analysed the changes in the proteome of human primary erythroid progenitor cells by treatment with decitabine, a known, yet not clinically safe, gamma-globin inducer. Significant differentially expressed proteins were identified which were involved in various biological pathways and functional categories.
2020-01-23 | PXD006889 | Pride
Project description:This study evaluated primary CD4+ T cell gene expression treated with pharmacologically achievable concentration (340 nM) of SAHA for 24 hours in order to evaluate potential side effects of this compound in cells relevant to HIV infection. Analysis of human primary CD4+ T cells taken from 9 healthy donors treated with 340 nM of SAHA for 24 hours. Results identify genes modulated by SAHA treatment in human primary CD4+ T cells.
2012-10-12 | E-GEOD-41504 | biostudies-arrayexpress
Project description:ChIP-seq analysis of chromatin state plasticity in primary human adult erythroid progenitor cells
| PRJNA230472 | ENA